^
No biomarker
Ewing Sarcoma
dactinomycin
Sensitive: A1 - Approval
No biomarker
Ewing Sarcoma
IE
Sensitive: A2 - Guideline
No biomarker
Ewing Sarcoma
VC
Sensitive: A2 - Guideline
No biomarker
Ewing Sarcoma
GT
Sensitive: A2 - Guideline
No biomarker
Ewing Sarcoma
melphalan + busulfan
Sensitive: A2 - Guideline
No biomarker
Ewing Sarcoma
ifosfamide + cyclophosphamide oral + etoposide IV + topotecan
Sensitive: A2 - Guideline
No biomarker
Ewing Sarcoma
temozolomide + irinotecan
Sensitive: A2 - Guideline
No biomarker
Ewing Sarcoma
temozolomide + irinotecan + vincristine
Sensitive: A2 - Guideline
No biomarker
Ewing Sarcoma
cyclophosphamide oral + topotecan
Sensitive: A2 - Guideline
No biomarker
Ewing Sarcoma
carboplatin + ifosfamide + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Ewing Sarcoma
gemcitabine + docetaxel
Sensitive: A2 - Guideline
No biomarker
Ewing Sarcoma
cabozantinib tablet
Sensitive: A2 - Guideline
TMB-H
Ewing Sarcoma
pembrolizumab
Sensitive: A2 - Guideline
MSI-H/dMMR
Ewing Sarcoma
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Ewing Sarcoma
VIDE
Sensitive: A2 - Guideline
No biomarker
Ewing Sarcoma
VAI
Sensitive: A2 - Guideline
No biomarker
Ewing Sarcoma
VDC
Sensitive: A2 - Guideline
No biomarker
Ewing Sarcoma
SP2577
Sensitive: B - Late Trials
No biomarker
Ewing Sarcoma
TK216
Sensitive: B - Late Trials
MGMT promoter methylation
Ewing Sarcoma
temozolomide + irinotecan
Sensitive: C2 – Inclusion Criteria
IGF1R underexpression
Ewing Sarcoma
mTOR inhibitor + IGF-1R inhibitor
Sensitive: C3 – Early Trials
IGF1 elevation
Ewing Sarcoma
CP-751,871
Sensitive: C3 – Early Trials
PTPRD R995C
Ewing Sarcoma
mTOR inhibitor + IGF-1R inhibitor
Sensitive: C3 – Early Trials
PTPRD V253I + PTPRD W775stop
Ewing Sarcoma
mTOR inhibitor + IGF-1R inhibitor
Sensitive: C3 – Early Trials
PTPRD V253I + PTPRD W775stop
Ewing Sarcoma
IGF-1R inhibitor
Sensitive: C3 – Early Trials
SPARC overexpression
Ewing Sarcoma
albumin-bound paclitaxel
Sensitive: C3 – Early Trials
EWSR1-FLI1 fusion
Ewing Sarcoma
VDC
Sensitive: C4 – Case Studies
FGFR3 amplification + FGFR4 amplification + FLT4 amplification
Ewing Sarcoma
trametinib + pazopanib
Resistant: C4 – Case Studies
IGF1R expression
Ewing Sarcoma
IGF-1R inhibitor
Sensitive: D – Preclinical
EWSR1-FLI1 fusion
Ewing Sarcoma
CDK12 inhibitor
Sensitive: D – Preclinical
FUS-ERG fusion
Ewing Sarcoma
ASP7487
Sensitive: D – Preclinical
CDKN2A deletion
Ewing Sarcoma
ASP7487
Sensitive: D – Preclinical
PAK4 deletion
Ewing Sarcoma
ASP7487
Sensitive: D – Preclinical
FUS-ERG fusion
Ewing Sarcoma
palbociclib
Sensitive: D – Preclinical
PAK4 deletion
Ewing Sarcoma
palbociclib
Sensitive: D – Preclinical
CDKN2A deletion
Ewing Sarcoma
palbociclib
Sensitive: D – Preclinical
CASP8 overexpression
Ewing Sarcoma
AMG 655
Sensitive: D – Preclinical
KDM1A overexpression
Ewing Sarcoma
SP2577
Sensitive: D – Preclinical